ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (47)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aalbers, R.
Right arrow Articles by Sybrecht, G.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aalbers, R.
Right arrow Articles by Sybrecht, G.W.
Eur Respir J 2002; 19:936-943
Copyright ©ERS Journals Ltd 2002


Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

R. Aalbers1, J. Ayres2, V. Backer3, M. Decramer4, P.A. Lier5, P. Magyar6, J. Malolepszy7, R. Ruffin8 and G.W. Sybrecht9

1 Martini Hospital, Groningen, The Netherlands. 2 Birmingham Heartlands Hospital, Birmingham, UK. 3 Bispebjerg Hospital, Copenhagen, Denmark. 4 UZ Gasthuisberg, Leuven, Belgium. 5 Humana Medical Centre, Sandvika, Norway. 6 Semmelweis University, Budapest, Hungary. 7 Dept of Internal Medicine and Allergology, Wroclaw Medical Hospital, Wroclaw, Poland. 8 The Queen Elizabeth Hospital, Woodville South, Australia. 9 Medical Hospital and Health Centre, Homburg, Germany

CORRESPONDENCE: G.W. Sybrecht, Medizinische Universitätskliniken, Inner Medizin V, D-66241, Homburg, Germany. Fax: 49 68411623602. E-mail: pngsyb@uniklinik-saarland.de

Keywords: bronchodilation, chronic obstructive pulmonary disease, formoterol

Received: April 27, 2001
Accepted January 9, 2002

This study was supported by AstraZeneca

The aim of this study was to investigate formoterol, an inhaled long-acting ß2-agonist, in patients with chronic obstructive pulmonary disease (COPD).

Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 µg b.i.d.) or placebo via Turbuhaler® for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits.

Compared with placebo, 18 µg b.i.d. formoterol reduced the mean total symptom score by 13% and increased the percentage of nights without awakenings by 15%. Formoterol (9 and 18 µg b.i.d.) significantly reduced symptom scores for breathlessness (–7% and –9%, respectively) and chest tightness (–11% and –8%, respectively), reduced the need for rescue medication (–25% and –18%, respectively), and increased symptom-free days (71% and 86%, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen.

In conclusion, 9 and 18 µg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 µg b.i.d. and higher.




This article has been cited by other articles:


Home page
Therapeutic Advances in Respiratory DiseaseHome page
J. F. Donohue, N. A. Hanania, C. Fogarty, S. C. Campbell, M. Rinehart, and K. Denis-Mize
Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 199 - 208.
[Abstract] [PDF]


Home page
Proc Am Thorac SocHome page
P. T. Diaz, A. S. Bruns, M. E. Ezzie, N. Marchetti, and B. M. Thomashow
Optimizing Bronchodilator Therapy in Emphysema
Proceedings of the ATS, May 1, 2008; 5(4): 501 - 505.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin
Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review
Chest, May 1, 2008; 133(5): 1079 - 1087.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al.
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials
Thorax, February 1, 2008; 63(2): 122 - 128.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane
Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline
Ann Intern Med, November 6, 2007; 147(9): 639 - 653.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
D. E. O'Donnell
Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
M. Decramer
Tiotropium as essential maintenance therapy in COPD
Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
K. F. Rabe
Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies
Proceedings of the ATS, May 1, 2006; 3(3): 270 - 275.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S Scott, P Walker, and P M A Calverley
COPD exacerbations {middle dot} 4: Prevention
Thorax, May 1, 2006; 61(5): 440 - 447.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C.-Y. Chen, K.-Y. Yang, Y.-C. Lee, and P.-P. Perng
Effect of Oral Aminophylline on Pulmonary Function Improvement and Tolerability in Different Age Groups of COPD Patients
Chest, October 1, 2005; 128(4): 2088 - 2092.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
Eur. Respir. J., August 1, 2005; 26(2): 214 - 222.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, and for the COSMIC (COPD and Seretide: a Multi-Center
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
Thorax, June 1, 2005; 60(6): 480 - 487.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. J. van der Woude, J. Zaagsma, D. S. Postma, T. H. Winter, M. van Hulst, and R. Aalbers
Detrimental Effects of {beta}-Blockers in COPD: A Concern for Nonselective {beta}-Blockers
Chest, March 1, 2005; 127(3): 818 - 824.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell
Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study
Chest, September 1, 2004; 126(3): 926 - 934.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. R. Sutherland and R. M. Cherniack
Management of Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., June 24, 2004; 350(26): 2689 - 2697.
[Full Text] [PDF]


Home page
ChestHome page
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter
Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis
Chest, June 1, 2004; 125(6): 2309 - 2321.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
B J Smith, S L Appleton, A J Veale, H J McElroy, D Veljkovic, and L Saccoia
Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol
Chronic Respiratory Disease, April 1, 2004; 1(2): 63 - 69.
[Abstract] [PDF]


Home page
ChestHome page
D. P. Tashkin and C. B. Cooper
The Role of Long-Acting Bronchodilators in the Management of Stable COPD
Chest, January 1, 2004; 125(1): 249 - 259.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen
Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
JAMA, November 5, 2003; 290(17): 2301 - 2312.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, and H. Olsson
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Eur. Respir. J., January 1, 2003; 21(1): 74 - 81.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the European Respiratory Society.